All In Biotech

Drug Trial Radar · NCT05252338

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults

A Phase 1, Open-label, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational Seasonal Quadrivalent Influenza mRNA Vaccine CVSQIV Administered Intramuscularly in Healthy Younger and Older Adults

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

240

Actual

Start

Feb 7, 2022

Primary completion

Sep 27, 2022

Study completion Sep 27, 2022

Sponsor

Lead sponsor
CureVacIndustry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Feb 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and reactogenicity profile of CVSQIV at different dose levels.

Conditions

  • Influenza

Interventions

  • CVSQIVBiological

    Participants will receive an intramuscular injection by needle in the deltoid area.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequencies of Grade 3 ARs and any SAR within at least 20 hours after the trial vaccine administration by dose level, for decisions on subsequent vaccination of additional sentinel subjects with the same dose level.Time frame: up to day 2
  2. The frequencies of Grade 3 ARs and any SAR within at least 60 hours after the trial vaccine administration by dose level, for decisions on dose escalation as well as continuation of enrollment at the same dose level.Time frame: up to day 3
  3. The frequencies, intensities and duration of solicited local ARs on the day of vaccination and the following 7 days by dose level, for the characterization of the safety and reactogenicity profile.Time frame: up to day 8
  4. The frequencies, intensities, duration and relationship to trial vaccination of solicited systemic AEs on the day of vaccination and the following 7 days by dose level, for the characterization of the safety and reactogenicity profile.Time frame: up to day 8
  5. The occurrence, intensities and relationship to trial vaccination of unsolicited AEs on the day of vaccination and the following 28 days by dose level, for the characterization of the safety and reactogenicity profile.Time frame: up to day 29
  6. The occurrence and relationship to trial vaccination of SAEs and AESIs throughout the trial, for the characterization of the safety and reactogenicity profile.Time frame: through study completion, an average of 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • International Vaccination and Research Center (CEVAXIN) Panama Clinic, Ramon H Jurado Street, Pacific Center, Level 12

    Panama City, Panama

  • Unidad de Investigación Clínica INDICASAT AIP / Hospital Paitilla

    Panama City, Panama

  • International Vaccination and Research Center (CEVAXIN) Avenida Mexico, 33 Street

    Panama City, Calidonia, Panama City, Panama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.